Suvorexant’s “Twilight Zone”: Advisory Panel, FDA Favor Low Dose; Merck Does Not
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA and its advisors seem to support lowering the proposed dose for Merck insomnia treatment suvorexant as a way to save the marketing application, but Merck appears insistent that the lower 10 mg dose doesn’t work.